Question 1

What is Cortagen and where does it come from?

Accepted Answer

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) produced by directed synthesis based on amino-acid analysis of the cerebral-cortex peptide extract Cortexin; it is one of the Russian 'short peptide bioregulators' (cytogens) studied in aging-related research (Anisimov SV et al., 2004, Neuro Endocrinol Lett, PMID 15159690). It is a research-use-only material, not a medicine.

Question 2

What does the peer-reviewed research base actually look like?

Accepted Answer

Limited peer-reviewed data. The indexed literature is sparse (about 15 PubMed records), mostly in vitro and rodent studies originating largely from one research group, several published in Russian, and includes some null results. No registered or controlled human efficacy trials were located, so findings should be treated as early and preliminary.

Question 3

What has been studied in nerve-regeneration models?

Accepted Answer

In rat sciatic-nerve injury models, Cortagen was reported to increase regenerating-fiber growth rate and nerve conduction velocity, with a follow-up describing a delayed effect on restoration of injured-nerve function (Turchaninova et al., 2000, Bull Exp Biol Med, PMID 11276314; Kolosova et al., 2002, Dokl Biol Sci, DOI 10.1023/a:1016098302564). These are animal-model observations and do not establish effects in humans.

Question 4

Is there research on antioxidant or epigenetic ('anti-aging') mechanisms?

Accepted Answer

In rats, Cortagen reduced markers of lipid peroxidation and oxidative protein modification (Kozina, 2007, Bull Exp Biol Med, DOI 10.1007/s10517-007-0230-8), and in cultured lymphocytes from elderly donors it was associated with ribosomal-gene activation and chromatin decondensation (Khavinson, Lezhava & Malinin, 2004, Bull Exp Biol Med, DOI 10.1023/b:bebm.0000024393.40560.05). These are mechanistic, cell-level and animal-level research findings, not proof of a clinical anti-aging benefit.

Question 5

Are there reports where Cortagen showed little or no effect?

Accepted Answer

Yes, and honest reporting matters. Cortagen showed no comitogenic effect on mouse thymocyte proliferation (Khavinson et al., 2002, Bull Exp Biol Med, DOI 10.1023/a:1019830308824) and, unlike the related peptide epithalon, did not change immunity or hemostasis measures in hypophysectomized or aged birds (Kuznik et al., 2008, Adv Gerontol, PMID 19432169). Observed effects in research appear tissue- and context-dependent rather than uniform.

Question 6

What is known about dosing?

Accepted Answer

This is research-use-only material and the following is not medical advice. Research-reported parameters come only from animal models (for example, 10 ug/kg intramuscular in rats; Turchaninova et al., 2000, PMID 11276314), research-reported ranges vary, and they do not translate to human dosing; refer to your study's protocol reference rather than any general guidance. Human dosing has not been established in the indexed literature.

Question 7

How should marketing claims about Cortagen for cognition or 'nerve repair' be interpreted?

Accepted Answer

Cautiously. Vendor and blog claims currently outrun the peer-reviewed record: the indexed studies are preclinical, partly null, and concentrated in one research lineage, and no controlled human efficacy trials were located. Strong human-benefit claims should be treated as unsupported by the current research evidence.

Phase	Daily reference amount	Units / volume
Weeks 1–2	1000 mcg	15 units (0.15 mL)
Weeks 3–4	2000 mcg	30 units (0.30 mL)

Cortagen.

Calculated volume reference

Cited protocol & reconstitution guide